TEVA PHARMACEUTICAL INDUSTRIES LIMITED Deferred Income Tax Assets, Net
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVJF) had Deferred Income Tax Assets, Net of $2.16 billion as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredIncomeTaxAssetsNet · last filed 2026-07-29
- 2026-06-30: Deferred Income Tax Assets, Net $2.16B.
- 2026-03-31: Deferred Income Tax Assets, Net $2.19B.
- 2025-12-31: Deferred Income Tax Assets, Net $2.19B.
- 2025-09-30: Deferred Income Tax Assets, Net $1.63B.
| Period end | Deferred Income Tax Assets, Net | Deferred Income Tax Assets, Net as first filed |
|---|---|---|
| 2026-06-30 | $2.16B 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $2.19B 10-Q · filed 2026-04-29 | |
| 2025-12-31 | $2.19B 10-Q · filed 2026-07-29 | |
| 2025-09-30 | $1.63B 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $1.78B 10-Q · filed 2025-07-30 | |
| 2025-03-31 | $1.76B 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $1.80B 10-K · filed 2026-02-03 | |
| 2024-09-30 | $2.07B 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $2.00B 10-Q · filed 2024-07-31 | |
| 2024-03-31 | $1.96B 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $1.81B 10-K · filed 2025-02-05 | |
| 2023-09-30 | $1.75B 10-Q · filed 2024-11-06 | $1.75B 10-Q · filed 2023-11-09 |
| 2023-06-30 | $1.58B 10-Q · filed 2024-07-31 | $1.58B 10-Q · filed 2023-08-02 |
| 2023-03-31 | $1.58B 10-K · filed 2024-02-12 | $1.57B 10-Q · filed 2023-05-10 |
| 2022-12-31 | $1.46B 10-K · filed 2024-02-12 | $1.45B 10-K · filed 2023-02-10 |
| 2022-09-30 | $1.55B 10-K · filed 2024-02-12 | |
| 2022-06-30 | $1.59B 10-K · filed 2024-02-12 | |
| 2022-03-31 | $637.00M 10-Q · filed 2022-05-03 | |
| 2021-12-31 | $596.00M 10-K · filed 2023-02-10 | |
| 2021-09-30 | $622.00M 10-Q · filed 2021-10-27 | |
| 2021-06-30 | $645.00M 10-Q · filed 2021-07-28 | |
| 2021-03-31 | $691.00M 10-Q · filed 2021-04-28 | |
| 2020-12-31 | $695.00M 10-K · filed 2022-02-09 | |
| 2020-09-30 | $509.00M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $483.00M 10-Q · filed 2020-08-05 | |
| 2019-12-31 | $386.00M 10-K · filed 2021-02-10 |